Cassava Sciences, Inc. (NASDAQ:SAVA – Get Ranking) insider James William Kupiec bought 2,500 shares of the corporate’s inventory in a transaction on Tuesday, August 23rd. The inventory was acquired at a median worth of $24.44 per share, with a complete worth of $61,100.00. Following the acquisition, the insider now owns 2,500 shares of the corporate’s inventory, valued at $61,100. The acquisition was disclosed in a authorized submitting with the SEC, which is on the market at the SEC web site.
Cassava Sciences Worth Efficiency
Shares of NASDAQ:SAVA traded up $2.52 on Wednesday, reaching $27.83. The corporate’s inventory had a buying and selling quantity of three,258,404 shares, in comparison with its common quantity of two,008,349. The inventory’s 50-day transferring common is $23.70 and its two-hundred day transferring common is $28.93. Cassava Sciences, Inc. has a 52-week low of $13.84 and a 52-week excessive of $100.00. The inventory has a market capitalization of $1.12 billion, a P/E ratio of -18.28 and a beta of 0.68.
Institutional Buyers Weigh In On Cassava Sciences
Quite a few institutional buyers and hedge funds have lately made adjustments to their positions in SAVA. Commonwealth Fairness Companies LLC raised its holdings in shares of Cassava Sciences by 11.2% within the fourth quarter. Commonwealth Fairness Companies LLC now owns 11,820 shares of the corporate’s inventory valued at $516,000 after shopping for an extra 1,195 shares over the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Cassava Sciences by 25.1% within the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,045 shares of the corporate’s inventory valued at $220,000 after shopping for an extra 1,011 shares over the last quarter. Advisor Group Holdings Inc. raised its holdings in shares of Cassava Sciences by 13.0% within the fourth quarter. Advisor Group Holdings Inc. now owns 43,253 shares of the corporate’s inventory valued at $1,892,000 after shopping for an extra 4,965 shares over the last quarter. Envestnet Asset Administration Inc. bought a brand new stake in shares of Cassava Sciences within the fourth quarter valued at about $219,000. Lastly, ProShare Advisors LLC raised its holdings in shares of Cassava Sciences by 71.5% within the fourth quarter. ProShare Advisors LLC now owns 8,400 shares of the corporate’s inventory valued at $366,000 after shopping for an extra 3,501 shares over the last quarter. 34.01% of the inventory is owned by hedge funds and different institutional buyers.
Analyst Rankings Modifications
Quite a few brokerages lately commented on SAVA. B. Riley lowered their goal worth on shares of Cassava Sciences from $58.00 to $44.00 and set a “purchase” ranking for the corporate in a analysis be aware on Thursday, August 11th. HC Wainwright restated a “purchase” ranking on shares of Cassava Sciences in a analysis be aware on Thursday, August 4th.
About Cassava Sciences
Cassava Sciences, Inc, a medical stage biotechnology firm, develops medication for neurodegenerative illnesses. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is accomplished Section 2b medical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer’s illness.
Additional Studying
This on the spot information alert was generated by narrative science expertise and monetary knowledge from MarketBeat with a view to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you take into account Cassava Sciences, you will need to hear this.
MarketBeat retains monitor of Wall Road’s top-rated and greatest performing analysis analysts and the shares they suggest to their shoppers every day. MarketBeat has recognized the 5 shares that high analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Cassava Sciences wasn’t on the listing.
Whereas Cassava Sciences at present has a “Average Purchase” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.
